R&D
TriOar is shaping a better, healthier future for those in need.
Our platform is multi-targetable with coverage that can be expanded.
The Triore platform is Triore's own treatment-based technology and is designed to have equal or greater efficacy in a small amount.
It can act on multiple targets and expand the scope of application.
Oar1 detects cancer lesions and allows drugs to be absorbed quickly.
Oar2 specifically targets cancer cells.
Oar3 quickly induces cancer cell death.
The Triore platform targets cancer lesions sequentially and reaches cancer cells quickly and accurately.
It has improved safety because it has anti-cancer function only in cancer lesions.
The Triore platform is very scalable.
It can be applied to various action patterns (drug complex, immuno-cancer drug, etc.).
It can be applied to cancer and other disease groups (inflammatory, autoimmune, etc.).
CEO : Woo Seongho ㅣ Business License : 302-86-01952
Head office ㅣ 2nd floor, 39 Techno 4-Ro, Yuseong-gu, Daejeon
Tel. 042-931-3911ㅣ Fax. 042-933-3912
E-mail. trioar@trioar.co.kr
Copyright ⓒ TRIOAR. ALL rights reserved.
Hosting by ALLONECARE